Myriad Genetics, Inc.

NASDAQ:MYGN   3:59:42 PM EDT
26.85
-0.66 (-2.40%)
Other Pre-Announcement

Myriad Genetics Delivers 12% Sequential Revenue Growth In March 2021 Quarter

Published: 05/03/2021 20:18 GMT
Myriad Genetics, Inc. (MYGN) - Myriad Genetics Delivers 12% Sequential Revenue Growth in March 2021 Quarter, Company Executes on Strategic Transformation Initiatives.
Quarterly Adjusted Loss per Share $0.06.
Quarterly GAAP Loss per Share $0.52.
Quarterly Revenue Rose 6 Percent to $173.1 Million.
Q1 Earnings per Share View $-0.14, Revenue View $156.2 Million -- Refinitiv Ibes Data (analyst estimates).
Qtrly Total Test Volumes Increase 5% Sequentially.
Will Not Provide Financial Guidance for Quarter Ending June 30, 2021 Or Fiscal Year 2021.